Pour sa première édition des séminaires prestiges organisés par notre unité BRIC, nous sommes heureux d’accueillir Dr Olivier Delattre, Directeur de Recherche à l’Institut Curie, directeur de l’unité U830 « Cancer, Hétérogénéité, Instabilité et Plasticité » (CHIP) et « Grand prix INSERM 2022 ».

Nous profiterons de sa venue pour organiser des rencontres avec les chercheurs et étudiants de notre unité.

Séminaire à 17h le mardi 6 février 2024, salle de conférence du BBS, 2 rue Dr Hoffmann Martinot.

Dr. Olivier Delattre is MD-PhD, trained in pediatric oncology. He is Research Director at Inserm and heads the Research Unit U830 “Cancer, Heterogeneity, Instability and Plasticity” (CHIP) and the research team “Diversity and plasticity of children tumours” (DePiCT) at the Institut Curie (Paris). He has also created the Somatic Genetics Unit, aimed to transfer research results to the clinic, and heads the “Genetic and Biology of Cancer” department at the Institut Curie. He also leads the SIREDO Center (Care, Innovation, Research in Oncology of Children, Adolescent and Young Adults) at the Institut Curie, gathering clinicians and researchers to accelerate the development of new therapeutic strategies for pediatric cancers. His lab identified some key genetic alterations in Ewing sarcoma, rhabdoid tumors, neuroblastoma as well as in various sarcomas, and also the Neurofibromatosis type 2 (NF2) tumour suppressor gene. His lab investigates the functional consequences of these alterations in tumour development, and has established cellular and animal models. His current fields of interest are the study of genetic alterations associated with pediatric cancers, the study of pediatric cancers cells-of-origin and the mechanisms of cancer cells phenotypic plasticity. Dr Delattre has published more than 400 papers, many of them in the most prestigious journals such as Nature, Nature Genetics, Nature Medicine, Cancer Cell, Molecular Cell, New England Journal of Medicine…, with an H-index of 102. He received numerous awards including the “Association pour la Recherche sur le Cancer (ARC)-Leopold Griffuel” award in 2016, the “Grand Prix de la Recherche Inserm” in 2022, and the “American Association for Cancer Research (AACR)-St. Baldrick’s Foundation” Award for Outstanding Achievement in Pediatric Cancer Research in 2023. He is an elected member of EMBO (European Molecular Biology Organization).

🎤 Ewing sarcoma: From genetics to epigenetics and immunology.

Ewing sarcoma is a bone cancer mostly observed in children and young adults. The EWSR1::FLI1 gene fusion (Nature 1992) is a key driver of this malignancy (J. Clin. Oncol. 1996, 2010; Cancer Discov. 2014). It completely reprograms the Ewing cell-of-origin (Cancer Cell 2007; Cancer Res. 2021) through direct binding at GGAA microsatellites and subsequent transformation of these sequences into bona fide enhancers (PLoS One 2009; Nature Genetics 2015; Nature Medicine 2017; Nat Rev Dis Primers 2018). Activation of GGAA microsatellites also leads to specific transcription of intergenic regions (Cancer Cell 2021, 2022; Mol Cell, 2022; Cell Rep. 2022). Recent data of the laboratory indicate that some of these transcripts can be translated thus leading to important applications for immunotherapy.

🤝 Si des scientifiques extérieurs à l’unité BRIC souhaitent rencontrer le Dr Olivier Delattre, veuillez contacter Thomas Mathivet : thomas.mathivet@inserm.fr